IOL Chemicals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
IOL Chemicals and Pharmaceuticals Ltd is strategically positioning itself for long-term growth through a significant Rs 495-crore capital expenditure plan aimed at expanding its API business and diversifying into higher-value segments. Management's focus on increasing Ibuprofen capacity by 50% and entering the CDMO space reflects a commitment to meeting global demand while enhancing operational efficiency. This diversification strategy is expected to drive revenue growth and margin expansion, aligning with Vista's forecast of accelerating revenue growth and improving margins. The company's proactive approach to managing input price volatility and its ability to pass costs onto customers further supports this positive outlook. However, potential execution risks associated with concurrent projects and the need to maintain high utilization rates in a competitive landscape remain watchpoints. The Indian pharma API sector is expanding, bolstered by improving pricing power and geopolitical stability, which enhances IOL's competitive position. Over the next 12-24 months, key opportunities include scaling non-Ibuprofen products and deepening market presence, while headwinds may arise from regulatory changes and dependence on high-volume markets
Why We Like This Stock
- Significant capital expenditure plan to expand API capacity and diversify into higher-value segments
- Management's ability to pass on input cost increases supports margin expansion
- Strong domestic fundamentals and government support enhance growth prospects
Things To Watch Out For
- Execution risks associated with concurrent expansion projects could impact operational efficiency
- Dependence on high-volume US markets poses revenue risks amid geopolitical tensions
- Potential regulatory changes may affect operational dynamics and market access
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,133 | 2,079 | 2,319 | 2,795 | 3,227 |
| Profit Before Tax (Cr.) | 183 | 138 | 195 | 254 | 288 |
| PBT Margin | 8.6% | 6.6% | 8.4% | 9.1% | 8.9% |
| Net Profit (Cr.) | 145 | 113 | 152 | 199 | 225 |
| Earnings Per Share | 4.9 | 3.9 | 5.2 | 6.8 | 7.7 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. It operates through two segments: Pharmaceuticals and Specialty Chemicals. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to the food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, plasticizers and ploymers, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, antiplatelet, anti-cholesterol, anti-convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.